secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0001493152-23-020623
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte enters amended CEO employment agreement with Joshua Riggs; grants 1.15M options
--------------------------------------------------------------------------------

- Base salary $360,000, target bonus 50% of base salary, effective May 1, 2023.
- CEO Grant: options to purchase 350,000 shares, 25% vests at 1 year, balance monthly over 3 years.
- Performance Grant: options for 800,000 shares, vesting tied to VWAP targets ($0.54-$1.08) by Dec 31, 2025.
- Severance includes 12 months base salary, pro-rated bonus, health premium if terminated without cause or for good reason.
- Riggs appointed CEO Feb 24, 2023; this agreement amends and restates prior agreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223020623/0001493152-23-020623-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223020623/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-020623

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer